Deutsche Bank acknowledged positive data from AstraZeneca's tozorakimab for chronic obstructive pulmonary disease (COPD), presented at the ERS conference, supporting the drug's commercial potential. Despite this, the bank maintained a 'sell' rating on AstraZeneca shares with a target price of 11,500 pence, slightly below the current trading price. The data follows AstraZeneca's raised peak sales guidance above $5 billion, with consensus forecasts around $4 billion for 2030, suggesting room for modest upward revisions. The next key event will be analysts' reassessment of tozorakimab's revenue potential based on detailed COPD findings.
Jefferies has maintained a 'buy' rating on AstraZeneca with a price target of 17,500p, implying a 46% upside from the current share price. The broker expects AstraZeneca's third-quarter revenue to exceed consensus by about 1%, and core earnings befor...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
Citi has increased its target price for AstraZeneca to £186 from £178, maintaining a 'buy' rating after positive clinical developments, especially for the drug tozorakimab. The broker raised peak sales forecasts for tozorakimab to $7 billion and SERE...
AstraZeneca announced a $2 billion equity investment and clinical collaboration with Summit Therapeutics to develop ivonescimab, a first-in-class bispecific antibody for cancer treatment. This drug targets two cancer pathways simultaneously, potentia...
